RaymondDennisPrattMDFACP

PubMed

• 1 citations
  Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.
  Lingxiao Zhang, Liangying Gan, Kexin Li, Panpan Xie, Yan Tan
  European Journal of Clinical Pharmacology. 2022-09-01
• 1 citations
  Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety.
  Steven Fishbane, Tomas Ganz, Raymond D Pratt
  Current Medical Research and Opinion. 2022-08-01
• Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease.
  Liangying Gan, Panpan Xie, Yan Tan, Gang Wei, Xiaojuan Yuan
  Drugs in R&D. 2022-06-01

Journal Articles

• Donepezil in vascular dementia: a randomized, placebo-controlled study.  
  Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD, Neurology
• The induction of ATP energized mitochondrial volume changes by carcinogenic N-hydroxy-N-acetyl-aminofluorenes when combined with showdomycin. A unitary hypothesis for ...  
  Hadler HI, Daniel BG, Pratt RD, J.Antibiot
• Acylation of cholesterol by microsomal enzymes from mouse preputial gland tumors.  
  Grigor MR, Pratt RD, Snyder F, Arch.Biochem.Biophys
• Thyroid hormone. Aldosterone antagonism in cultured epithelial cells. Biochim.  
  Pratt RD, Johnson JP, Biophys.Acta
• Purification and characterization of the reconstitutively active phosphate transporter from rat liver mitochondria.  
  Kaplan RS, Pratt RD, Pedersen PL, J.Biol.Chem
• Purification and reconstitution of the phosphate transporter from rat liver mitochondria.  
  Kaplan RS, Pratt RD, Pedersen PL, Methods Enzymol
• Inhibition of Na+-dependent phosphate transport by group-specific covalent reagents in rat kidney brush border membrane vesicles. Evidence for the involvement of tyros...  
  Pratt RD, Pedersen PL, Arch.Biochem.Biophys
• Energy-linked anion transport. Cloning, sequencing, and characterization of a full length cDNA encoding the rat liver mitochondrial proton/phosphate symporter.  
  Ferreira GC, Pratt RD, Pedersen PL, J.Biol.Chem
• Mitochondrial proton/phosphate transporter. An antibody directed against the COOH terminus and proteolytic cleavage experiments provides new insights about its membran...  
  Ferreira GC, Pratt RD, Pedersen PL, J.Biol.Chem
• Mitochondrial phosphate transport. Import of the H+/Pi symporter and role of the presequence.  
  Pratt RD, Ferreira GC, Pedersen PL, J.Biol.Chem
• Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur.  
  Rogers SL, Doody RS, Pratt RD, Ieni JR, Neuropsychopharmacol
• A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.  
  Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD, Neurology
• Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia.  
  Pratt RD, J.Neurol.Sci
• Donepezil: tolerability and safety in Alzheimer's disease.  
  Pratt RD, Perdomo CA, Surick IW, Ieni JR, Int.J.Clin.Pract
• A balance study comparing dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers.  
  Martin P, Wang P, Robinson A, Poole L, Dragone J, Smyth M, Pratt R, AJKD
• Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled tr...  
  Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG, Int.J.Geriatr.Psychiatry
• Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients.  
  Reyes JF, Vargas R, Kumar D, Cullen EI, Perdomo CA, Pratt RD, Br.J.Clin.Pharmacol
• Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function.  
  Nagy CF, Kumar D, Cullen EI, Bolton WK, Marbury TC, Gutierrez MJ, Hutman HW, Pratt RD, Br.J.Clin.Pharmacol
• Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple ora...  
  Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD, Br.J.Clin.Pharmacol
• Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following mult...  
  Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA, Br.J.Clin.Pharmacol
• Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.  
  Spinowitz BS, Pratt RD, Curr Med Res Opin
• Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients.  
  Kwan JT, Pratt RD, Curr Med Res Opin
• Hyperphosphatemia of chronic kidney disease.  
  Hruska, KA, Matthew S, Lund R, Qiu P, and Pratt R, Kidney Int
• Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.  
  Malluche, HH, Pratt, R, Clin. Nephrol
• Reply: A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.  
  Smyth,M.D. and Pratt,R.D, Nephrol. Dial. Transplant
• Join now to see all

Abstracts/Posters

• Donepezil-treated patients with vascular dementia demonstrate cognitive and global benefits: results from Study 308, a 24-week, randomized, double-blind, placebo-contr...
  S Salloway, R Pratt, C Perdomo, and The Donepezil 308 Study Group, Neurobiol Aging
• Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
  Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, Arch.Neurol
• Pharmacokinetics and safety of donepezil HCL and levodopa/carbidopa in Parkinson's disease patients.
  C Okereke, D Kumar, E Cullen, R Pratt, W. Hahne, Eisai Inc. Int Psychogeriatr
• Pharmacokinetics of donepezil and risperidone in male subjects with schizophrenia.
  J Reyes, S Preskorn, A Khan, D Kumar, E Cullen, R Pratt, Int Psychogeriatr
• Results showing no clinically relevant pharmacokinetic interactions between donepezil hydrochloride and sertraline, risperidone or thioridazine.
  J Reyes, C Nagy, M Ravic, E Cullen, C Perdomo, R Pratt, J Am Geriatr Soc
• Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease.
  R Pratt, G Wilcock, A Whitehead, J Grimley Evans, J Birks, C Perdomo, J Am Geriatr Soc
• Pharmacokinetics of Epoetin Delta: A New Erythropoietin Produced by Gene-Activation in a Human Cell Line.
  Dowell, JA and Pratt, RD, ASN Annual Meeting
• Epoetin Delta for the Treatment of Anemia in Patients with CKD Not Requiring Hemodialysis,
  Pratt, RD, ASN Annual Meeting
• Serum Phosphorus levels are maintained and tablet burden is reduced by converting to lanthanum carbonate.
  Pratt, RD, ISN Nexus Symposium, ASN Annual Meeting
• Evolution of Renal Osteodystrophy over 1 and 2 years during treatment with Lanthanum Carbonate or standard phosphate binders.
  Malluche, HH and Pratt, RD, ISN Nexus Symposium, ASN Annual Meeting
• Lanthanum Carbonate: No evidence of adverse effects on liver after 6 years of treatment in patients with CKD Stage 5.
  Hutchison, A and Pratt, RD, ISN Nexus Symposium, ISN Nexus Symposium
• Effficacy of Lanthanum Carbonate monotherapy in CKD stage 5 patients previously receiving alternative phosphate binder therapy.
  Hutchison, A and Pratt, RD, ISN Nexus Symposium
• Donepezil is well tolerated in patients with vascular dementia: a comparison of safety and tolerability results from randomized, placebo-controlled trials in vascular ...
  R Pratt, C Perdomo, and The Donepezil 307 and 308 Study Groups, Neurobiol Aging
• Patients with vascular dementia differ from patients with Alzheimer's disease with respect to population characteristics and pattern of cognitive decline.
  C Perdomo, R Pratt, and the Donepezil 307 and 308 Study Groups, Neurobiol Aging
• Donepezil improves cognition in patients with vascular dementia: results from Study 307, a 24-week, randomized, double-blind, placebo-controlled trial.
  G Roman, R Pratt, C Perdomo, and The Donepezil 307 Study Group, Neurobiol Aging
• Purification and Characterization of the Reconstitutively Active Pi/H+ Symporter from Rat Liver Mitochondria.
  Kaplan, R.S., Pratt, R.D. and Pedersen, P.L, ASBC Meeting, Washington, D.C
• Lanthanum Carbonate versus Standard Therapy: No Difference in the Evolution of Renal Osteodystrophy in a Large Patient Population.
  Raymond Pratt and Michael Smyth, XLIV ERA-EDTA Congress, Barcelona, Spain
• Is One Year sufficient to observe Changes in Renal Osteodystrophy? Evaluation of Serial Bone Biopsies.
  Raymond Pratt and Michael Smyth, XLIV ERA-EDTA Congress, Barcelona, Spain
• Effective Reduction of Serum Phosphorus using Lanthanum Carbonate, with fewer tablets than Sevelamer Hydrochloride.
  Raymond Pratt and Michael Smyth, XLIV ERA-EDTA Congress, Barcelona, Spain
• The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.
  Pierce D, Pratt R, Martin P and Poole L, NKF Clinical Meetings
• Reduction of dietary phosphorus absorption with lanthanum carbonate and sevelamer carbonate: a balance study.
  Pratt R, Martin P, Poole L and Dragone J, NKF Clinical Meetings
• Toward A Rational Basis For Phosphate Binder Prescribing: Estimating The Binding Capacity Of Available Binders.
  Pratt, R and Smyth, M, ASN Scientific Sessions
• Estimating the binding capacity of available phosphate binders: a rational basis for prescribing.
  Copley JB, Pratt R, and Smyth, M, Oral Presentation Annual Dialysis Conference
• Pharmacokinetics and safety of concurrent donepezil HCI andlevodopa/carbidopa administration in subjects with Parkinson's disease.
  Okereke C, Kumar D, Cullen E, Pratt RD, Hahne W, Neurology
• Donepezil improves cognition and global function in Alzheimer’s disease: Results from US and multinational Phase III clinical trials.
  Petit, H., Doody, R.S., and Pratt, R.D, ECNP Paris France
• Join now to see all